---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-085398"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-07-28T23:59:59+00:00"
generated_at: "2026-06-12T23:09:19.790691+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NRX Pharmaceuticals amends Streeterville note; receives Nasdaq MVLS delisting notice

## Summary
- Amendment #2 to $11.02M convertible note: $1.8M cash paid July 10, then $400K/month through Dec 2023, payable in cash or shares.
- Company may pay redemption amounts in common stock even if Equity Conditions Failure exists; Streeterville waived prior defaults.
- Nasdaq notified NRXP on July 20 that MVLS fell below $50M; 180-day cure period until Jan 22, 2024, for continued listing.
- Redemption Premium continues on all payments; shareholder dilution possible from share conversions.

## SEC filing metadata
- accession: 0001104659-23-085398
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923085398/0001104659-23-085398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923085398/tm2317653d9_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-085398
- JSON: https://secwatch.observer/filing/0001104659-23-085398.json
- Plain text: https://secwatch.observer/filing/0001104659-23-085398.txt

## Key facts
- Listing & Compliance Notices
  NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A)
  source text: July 20, 2023, the Company received a written notification (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities (“MVLS”) because the Company has not maintained a minimum MVLS of $50,000,000 for the last thirty-three (33) consecutive business days. Nasdaq’s Notice has no immediate effect on the listing of the common stock on The Nasdaq Global Market and, at this time, the common stock will continue to trade on The Nasdaq Global Market under the symbol “NRXP”. Pursua
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923085398/0001104659-23-085398-index.htm
- Material Agreements
  NRX Pharmaceuticals, Inc. amended Amendment #2 to Convertible Promissory Note with Streeterville Capital, LLC (effective 2023-07-07).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: Streeterville Capital, LLC
  - Effective: 2023-07-07
  source text: On July 7, 2023, NRX Pharmaceuticals, Inc. (the “Company”) entered into Amendment #2 to Convertible Promissory Note (the “Second Amendment”), with Streeterville Capital, LLC (the “Streeterville”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923085398/0001104659-23-085398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.